FARON PHARMACEUTICALS OY
Develops myeloid cell-targeting immunotherapies for solid and hematological cancers.
FARN | IL
Overview
Corporate Details
- ISIN(s):
- FI4000153309
- LEI:
- 7437009H31TO1DC0EB42
- Country:
- Finland
- Address:
- Joukahaisenkatu 6, FI-20520 TURKU
- Website:
- https://faron.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Faron Pharmaceuticals Oy is a global, clinical-stage biopharmaceutical company dedicated to developing innovative cancer treatments by leveraging the patient's immune system. The company focuses on addressing unmet medical needs in oncology through novel immunotherapies. Its lead asset, bexmarilimab, is a first-in-class, macrophage-targeting anti-Clever-1 antibody currently in Phase I/II clinical trials. Faron is investigating bexmarilimab's potential to improve the efficacy of standard-of-care treatments for patients with hematological malignancies and solid tumors, aiming to bring the benefits of immunotherapy to a broader patient population. The company's pipeline originates from academic discoveries, establishing it as a pioneer in myeloid cell-targeting therapies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-04 08:00 |
Regulatory News Service
Faron announces two bexmarilimab abstracts accepted at ASH 2025, including an o…
|
English | 11.5 KB | ||
| 2025-11-03 08:00 |
Legal Proceedings Report
Faron hits key milestone with BEXMAB Phase 2 completion, advances to registrati…
|
English | 9.6 KB | ||
| 2025-10-28 08:00 |
Share Issue/Capital Change
Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rig…
|
English | 10.2 KB | ||
| 2025-10-21 15:10 |
Major Shareholding Notification
FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
|
English | 49.7 KB | ||
| 2025-10-20 08:00 |
Earnings Release
Updated BEXMAB Phase I/II Data presented at ESMO 2025 shows further improvement…
|
English | 17.4 KB | ||
| 2025-10-03 12:00 |
Share Issue/Capital Change
Faron Pharmaceuticals Ltd: Registration of New Shares
|
English | 7.5 KB | ||
| 2025-10-03 08:00 |
Share Issue/Capital Change
Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rig…
|
English | 10.2 KB | ||
| 2025-09-19 08:00 |
Director's Dealing
Faron Pharmaceuticals Ltd: Exercise of Options, Director Dealing and Issue of E…
|
English | 26.4 KB | ||
| 2025-09-12 17:25 |
Earnings Release
Correction: FARON PHARMACEUTICALS LTD: HALF-YEAR FINANCIAL RESULTS 1 JANUARY – …
|
English | 127.9 KB | ||
| 2025-08-27 08:00 |
Earnings Release
FARON PHARMACEUTICALS LTD: HALF-YEAR FINANCIAL RESULTS 1 JANUARY – 30 JUNE 2025
|
English | 31.5 KB | ||
| 2025-08-19 08:00 |
Report Publication Announcement
Faron Pharmaceuticals Ltd: Notice of Half-Year Financial Results
|
English | 5.1 KB | ||
| 2025-08-18 08:00 |
Legal Proceedings Report
Inside Information: Faron to advance bexmarilimab into a registrational Phase 2…
|
English | 13.5 KB | ||
| 2025-08-08 16:00 |
Major Shareholding Notification
Faron Pharmaceuticals Ltd: Holding(s) in Company
|
English | 47.7 KB | ||
| 2025-08-08 09:30 |
Regulatory News Service
Faron announces extension to its key patent family around bexmarilimab and targ…
|
English | 9.7 KB | ||
| 2025-08-07 08:00 |
Capital/Financing Update
Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rig…
|
English | 10.1 KB |
Automate Your Workflow. Get a real-time feed of all FARON PHARMACEUTICALS OY filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for FARON PHARMACEUTICALS OY
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for FARON PHARMACEUTICALS OY via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
